129 related articles for article (PubMed ID: 29403290)
1. Apatinib-treated advanced medullary thyroid carcinoma: a case report.
Chen K; Gao Y; Shi F; Cao G; Bao J
Onco Targets Ther; 2018; 11():459-463. PubMed ID: 29403290
[TBL] [Abstract][Full Text] [Related]
2. Treatment of medullary thyroid carcinoma with apatinib: A case report and literature review.
Cai S; Deng H; Chen Y; Wu X; Guan X
Medicine (Baltimore); 2017 Dec; 96(50):e8704. PubMed ID: 29390263
[TBL] [Abstract][Full Text] [Related]
3. Recent Updates on the Management of Medullary Thyroid Carcinoma.
Kim BH; Kim IJ
Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
[TBL] [Abstract][Full Text] [Related]
4. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS; Jesus TT; Cardoso L; Soares P; Vinagre J
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511745
[TBL] [Abstract][Full Text] [Related]
5. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
[TBL] [Abstract][Full Text] [Related]
6. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma.
Lin H; Jiang X; Zhu H; Jiang W; Dong X; Qiao H; Sun X; Jiang H
Tumour Biol; 2016 Jan; 37(1):381-91. PubMed ID: 26219898
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.
Kapur S; Xiao H; Zakowski MF; Hameed MR; Levin MB
World J Oncol; 2014 Apr; 5(2):81-89. PubMed ID: 29147383
[TBL] [Abstract][Full Text] [Related]
8. Treating medullary thyroid cancer in the age of targeted therapy.
Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ
Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961
[TBL] [Abstract][Full Text] [Related]
9. Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report.
Deng L; Wang Y; Lu W; Liu Q; Wu J; Jin J
Onco Targets Ther; 2017; 10():1521-1525. PubMed ID: 28352185
[TBL] [Abstract][Full Text] [Related]
10. Apatinib treatment in extensive metastatic advanced thymic carcinoma.
He Y; Liu S; E M; Wang C; Shi M; Liu G; Abiyasi N
J Biol Regul Homeost Agents; 2018; 32(3):693-697. PubMed ID: 29921401
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib for the treatment of advanced medullary thyroid cancer.
Nagilla M; Brown RL; Cohen EE
Adv Ther; 2012 Nov; 29(11):925-34. PubMed ID: 23104465
[TBL] [Abstract][Full Text] [Related]
12. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature.
Dora JM; Canalli MH; Capp C; Puñales MK; Vieira JG; Maia AL
Thyroid; 2008 Aug; 18(8):895-9. PubMed ID: 18651801
[TBL] [Abstract][Full Text] [Related]
13. Putative BRAF activating fusion in a medullary thyroid cancer.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
Cold Spring Harb Mol Case Stud; 2016 Mar; 2(2):a000729. PubMed ID: 27148585
[TBL] [Abstract][Full Text] [Related]
14. New drugs for medullary thyroid cancer: new promises?
Spitzweg C; Morris JC; Bible KC
Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
[TBL] [Abstract][Full Text] [Related]
15. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
17. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.
Giunti S; Antonelli A; Amorosi A; Santarpia L
Int J Endocrinol; 2013; 2013():803171. PubMed ID: 23509459
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
19. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.
Deshpande HA; Sheth K; Sosa JA; Roman S
Clin Med Insights Oncol; 2012; 6():355-62. PubMed ID: 23133319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]